Will the FDA approve a gene therapy cure for a major disease before 2028?

Gene therapy has achieved curative results for rare diseases like sickle cell (Casgevy, Lyfgenia approved in 2023) and inherited retinal dystrophy. The pipeline includes gene therapies for hemophilia, muscular dystrophy, and potentially more common conditions. However, the 100,000-patient prevalence threshold eliminates most current gene therapy targets, which focus on rare diseases. Scaling gene therapy manufacturing for larger patient populations remains a major challenge. Therapies for conditions like hemophilia A (affecting ~30,000 in the US) might not meet the threshold.

Last updated: Mar 2, 2026

Resolves YES if the FDA approves a gene therapy providing functional cure (defined as one-time treatment with durable benefit lasting 2+ years) for a disease with US prevalence exceeding 100,000 before January 1, 2028. The approval must be for a non-rare disease.

Source: FDA BLA Approval Database / FDA Press Releases

Expected resolution: January 15, 2028